The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying stock for my portfolio?

| More on:
Young black colleagues high-fiving each other at work

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When the FTSE 100‘s second largest company rises significantly, that means many billions of pounds of market value are added. That’s what happened today (25 April) after the AstraZeneca (LSE: AZN) share price surged 5.5% to reach 12,004p.

As I write, the pharmaceutical giant is now sporting a £183bn market cap. That puts it just behind oil behemoth Shell (at £184bn).

What caused this large share price movement? Let’s find out.

A quarterly masterclass

The firm has just reported its first-quarter results today. Going into the release, analysts were forecasting core earnings per share (EPS) of $1.92 on total revenue of $11.84bn (at constant exchange rates).

The drugmaker breezed past these expectations. It achieved EPS of $2.06, a 13% year-on-year increase, on revenue of $12.68bn (a 19% rise).

Therefore, this represented a top-and-bottom earnings beat. And that’s what has sent the stock up.

This growth was driven by demand for its blockbuster oncology drugs, including Tagrisso for lung cancer and Calquence for leukaemia. Total oncology revenue grew 26% to $5.12bn.

Its Imfinzi (durvalumab) cancer treatment was approved in China in November. This is a huge but also complicated market. The firm appears to be working deftly with partners and regulators there. In the quarter, Imfinzi revenue increased 33% to $1.11bn.

Meanwhile, its other businesses that include rare diseases, plus respiratory and immunology, also saw double-digit growth.

On the dividend front, the company had already announced its plan to raise the annual payout by 7% for 2024. The yield stands at 2.2%.

Looking ahead, management reiterated its full-year guidance, which is for total revenue and core EPS to both rise by low double-digits to low-teens.

So there was no hat-trick here (a double beat and a guidance raise). Overall though, this was a quarterly masterclass from a truly wonderful company.


Now, one issue to bear in mind§ is that the firm is investing heavily in R&D and on marketing for new drug launches. Spending rose about 18% to $2.7bn for such things during the quarter.

Plus, it’s been getting the chequebook out for a few acquisitions recently. In February, for example, it snapped up Gracell Biotechnologies, a clinical-stage biopharma focused on cell therapies for cancer and autoimmune diseases, for around $1.2bn.

In the previous quarter, AstraZeneca reported an earnings miss, and the share price dropped 7%. So the stock can be quite volatile for a number of reasons, including rising costs and inevitable drug trial failures.

The stock is trading at around 17.5 times forward earnings. I don’t see that as overvalued.

The ageing population mega-trend

I’m very bullish on AstraZeneca long term and invested in the stock earlier this year.

The firm appears to have massive growth potential as global populations live longer. This is particularly the case in China, where the population of people over 60 years old is projected to reach 28% by 2040, according to the World Health Organization.

Over 20% of the firm’s revenue now comes from Asia and I expect that to increase steadily in future.

Meanwhile, its R&D pipeline is absolutely packed to the rafters with possible future blockbuster drugs (those that exceed $1bn in annual sales).

Therefore, despite the stock nearing an all-time high, I’d still consider investing in it today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has positions in AstraZeneca Plc. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Nvidia stock is becoming more affordable!

Nvidia stock is up 2,500% over five years, but the chip giant’s share split -- announced during its earnings report…

Read more »

Investing Articles

Are Rolls-Royce shares good for passive income?

Our writer is getting mixed messages about the Rolls-Royce dividend. But whatever happens, he thinks passive income hunters will be…

Read more »

Investing Articles

Could the Rolls-Royce share price end 2024 above £5?

As the Rolls-Royce share price continues its remarkable run, our writer considers where it might be at the end of…

Read more »

Investing Articles

UK stocks are hitting all-time highs! Yet these 2 still look cheap to me

The FTSE 100's on a roll. But it's still possible to pick bargain UK stocks, provided we know where to…

Read more »

Satellite on planet background
Investing Articles

At just under £14, can BAE Systems’ share price still be a prime FTSE 100 bargain? 

Despite its bullish price run, BAE Systems’ share price still looks undervalued to me and appears set for strong growth.

Read more »

Photo of a man going through financial problems
Investing Articles

2 dividend shares I’d avoid like the plague in today’s stock market

The UK stock market is full of high-yield dividend shares that could equate to a steady stream of passive income.…

Read more »

Abstract bull climbing indicators on stock chart
Investing Articles

£17,000 in savings? Here’s how I’d aim to turn that into a £29,548 annual second income!

Generating a sizeable second income can be life-enhancing and can be done from relatively small investments in high-dividend-paying stocks.

Read more »

Investing Articles

With as little as £300 a month invested, this stock could net £16,000 a year in passive income

Putting a few hundred pounds each month into the stock market could eventually generate a five-figure annual passive income, this…

Read more »